Table 1.
Clinical characteristics at last follow-up
| Clinical characteristics | Total (n=162) | Monoinfected (HCV; n=107) |
Coinfected (HIV–HCV; n=55) |
|---|---|---|---|
| Duration of follow-up, years | 4.1 ±1.7 | 4.1 ±1.6 | 4.0 ±1.9 |
| Age, years | 60 ±7 | 60 ±7 | 60 ±8 |
| BMI, kg/m2 | 28 ±6 | 29 ±6a | 27 ±5a |
| CAP, dB/m | 247 ±59 | 254 ±58a | 232 ±59a |
| Sex | |||
| Male, n (%) | 105 (65) | 67 (63) | 38 (69) |
| Female, n (%) | 57 (35) | 40 (37) | 17 (31) |
| Race | |||
| White, n (%) | 36 (22) | 22 (21) | 14 (25) |
| Black, n (%) | 124 (77) | 84 (79) | 40 (73) |
| Mixed race/other, n (%) | 2 (1) | 1 (1) | 1 (2) |
| Ethnicity: Hispanic or Latino, n (%) | 11 (7) | 4 (4) | 7 (13) |
| Risk | |||
| Drinks per week | 1 ±2 | 0 ±1 | 1 ±3 |
| HCV infection >20 years, n (%) | 81 (51) | 50 (47) | 31 (58) |
| History of IVDU, n (%) | 95 (59) | 61 (58) | 34 (62) |
| Diabetes, n (%) | 30 (19) | 19 (18) | 11 (20) |
| Smoking pack years | 10 ±10 | 11 ±11 | 9 ±9 |
| Lab data | |||
| AST, U/l | 24 ±12 | 23 ±10 | 26 ±16 |
| ALT, U/l | 21 ±15 | 18 ±9a | 25 ±22a |
| HIV viral load <40, n (%) | 51 (94) | ||
| CD4+ T-cell count, cells/mm3 | 705 ±324 |
Values are mean ±sd unless indicated otherwise.
a
P<0.05 between HCV and HIV–HCV groups. ALT, alanine aminotransferase; AST, aspartate transaminase; BMI, body mass index; CAP, controlled attenuation parameter; IVDU, intravenous drug use.